^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    LeukoPrint®

    Company:
    SeekIn
    Type:
    CE Marked
    Related tests:

    Details

    Evidence
    News
    LeukoPrint uses shallow whole-genome sequencing to identify copy number aberrations (CNA) in blood samples from leukemia patients to assist in diagnostic classification and risk stratification. LeukoPrint provides a cost-effective and simplified method for prompt and accurate CNA profiling in leukemia patients
    Cancer:
    Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
    Method:
    Shallow whole genome sequencing
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    04/07/22
    L
    -
    CE